Anti-VEGF or anti-VEGFR2 therapy significantly improves pathological changes induced by tumor-derived VEGF and confers survival advantages to tumor-bearing mice or cancer patients [14, 32, 40–41]. Here, VEGFA is linked to neoplasm.